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Surfactant protein D (SP-D) is expressed in the mucosal secretion of the lung and con-
tributes to the innate host defense against a variety of pathogens, including influenza A 
virus (IAV). SP-D can inhibit hemagglutination and infectivity of IAV, in addition to reducing 
neuraminidase (NA) activity via its carbohydrate recognition domain (CRD) binding to 
carbohydrate patterns (N-linked mannosylated) on NA and hemagglutinin (HA) of IAV. 
Here, we demonstrate that a recombinant fragment of human SP-D (rfhSP-D), containing 
homotrimeric neck and CRD regions, acts as an entry inhibitor of IAV and downregu-
lates M1 expression considerably in A549 cells challenged with IAV of H1N1 and H3N2 
subtypes at 2 h treatment. In addition, rfhSP-D downregulated mRNA levels of TNF-α, 
IFN-α, IFN-β, IL-6, and RANTES, particularly during the initial stage of IAV infection of 
A549 cell line. rfhSP-D also interfered with IAV infection of Madin Darby canine kidney 
(MDCK) cells through HA binding. Furthermore, rfhSP-D was found to reduce luciferase 
reporter activity in MDCK cells transduced with H1+N1 pseudotyped lentiviral particles, 
where 50% of reduction was observed with 10 µg/ml rfhSP-D, suggestive of a critical role 
of rfhSP-D as an entry inhibitor against IAV infectivity. Multiplex cytokine array revealed 
that rfhSP-D treatment of IAV challenged A549 cells led to a dramatic suppression of key 
pro-inflammatory cytokines and chemokines. In the case of pH1N1, TNF-α, IFN-α, IL-10, 
IL-12 (p40), VEGF, GM-CSF, and eotaxin were considerably suppressed by rfhSP-D 
treatment at 24 h. However, these suppressive effects on IL-10, VEGF, eotaxin and IL-12 
(p40) were not so evident in the case of H3N2 subtype, with the exception of TNF-α, 
IFN-α, and GM-CSF. These data seem to suggest that the extent of immunomodulatory 
effect of SP-D on host cells can vary considerably in a IAV subtype-specific manner. 
Thus, rfhSP-D treatment can downregulate pro-inflammatory milieu encouraged by IAV 
that otherwise causes aberrant inflammatory cell recruitment leading to cell death and 
lung damage.
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IAV–SA receptor interaction, virus particles are internalized 
via clathrin, resulting in clathrin-mediated endocytosis, or via 
caveolin/clathrin-independent mechanism (14, 15). Thus, acidic 
environment triggers M2 ion channel and transfers protons and 
potassium into the interior portion of the virion to dissociate M1 
protein from the ribonucleoprotein (RNP) (16). Acidification 
also initiates HA-mediated conformational changes, which leads 
to viral fusion and RNPs release into the cytoplasm, resulting in 
viral transcription and replication. It is, therefore, suggested that 
SA and its linkage are crucial for the initiation of IAV infection of 
both epithelial and immune cells. Thus, inhibition of SA receptor 
binding or enzymatic switching of SA-mediated linkages can 
confer cell resistance, and/or alter susceptibility to IAV infection. 
Hence, cell surface SA is considered as an important primary 
receptor and determinant of IAV tropism, contributing to induc-
tion of immune responses as well as to viral pathogenesis.
It is crucial to understand the molecular mechanisms of host 
defense against IAV in order to design novel anti-IAV strategies. 
SP-D binding to HA leads to a direct inhibition of cellular infec-
tion by preventing HA–SA receptor interaction (4). SP-D has 
been shown to bind HA-mediated glycosylation sites, identified as 
β-type inhibitor of IAV. This interaction is calcium dependent, and 
binding of SP-D to NA inhibits the release of progeny virions from 
infected cells (17, 18). It has been reported that recombinant full-
length porcine SP-D has a potent antiviral activity against a wide 
range of IAV by similar mechanisms, more than human SP-D due 
to structural differences, such as an additional loop in its CRD, an 
additional glycosylation site, and an additional cysteine in the col-
lagen domain (19). In this study, we have used a well-characterized 
recombinant homotrimeric fragment of human SP-D comprising 
neck and CRD region (rfhSP-D), and examined its ability to act 
as an entry inhibitor of IAV and pseudotyped viral particles, and 




The A/England/2009 (pH1N1) and the A/HK/99 (H3N2) strains 
were gifted by Wendy Barclay from the Imperial College, London 
and Leo Poon from the University of Hong Kong, respectively. 
The plasmids used to produce the H1+N1 pseudotyped lentiviral 
particles were obtained from Addgene. The pHIV-Luciferase 
plasmid was a gift from Bryan Welm (Addgene plasmid # 21375); 
psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260); 
and Vesicular Stomatitis Virus (VSV-G) was offered by Bob 
Weinberg (Addgene plasmid #8454). Monoclonal Anti-Influenza 
Virus H1 HA, A/California/04/2009 (H1N1)pdm09, Clone 5C12 
(produced in  vitro), NR-42019 and Polyclonal Anti-Influenza 
Virus H3 HA, A/Hong Kong/1/1968 (H3N2) (antiserum, Goat), 
NR-3118 were obtained from BEI Resources, NIAID, NIH, USA.
cell culture
Adenocarcinomic human alveolar basal epithelial cells (A549), 
Madin Darby Canine Kidney (MDCK), and human embryonic 
kidney (HEK) 293T cell lines were cultured in Dulbecco’s Modified 
inTrODUcTiOn
The innate immune system is composed of both cellular and 
humoral players to encounter invading pathogens. It is also an 
important component in the initiation and modulation of the 
adaptive immunity. To distinguish self from non-self, the innate 
immune system has evolved to recognize pathogen-associated 
molecular patterns through a number of pattern recognition 
receptors, including toll like receptors and C-type lectin receptors. 
Collectins are collagenous lectins, representing a crucial group 
of calcium-dependent pattern recognition molecules present in 
pulmonary secretions and mammalian serum (1). They play a 
crucial role in the first line of defense against a diverse range of 
pathogens by interacting with specific glycoconjugates and lipid 
moieties present on the surface of microorganisms. A significant 
number of in vitro and in vivo studies have focused on the immu-
nomodulatory functions of a lung collectin, human surfactant 
protein D (SP-D). SP-D is primarily organized into four regions: 
a cysteine-linked N-terminal region involved in multimerization, 
a triple-helical collagen region composed of Gly-X-Y repeats, an 
α-helical, coiled-coil trimerizing neck region, and the C-terminal 
carbohydrate recognition domains (CRDs) or C-type lectin 
domain (2). Human SP-D is primarily synthesized by alveolar type 
II and Clara cells, in addition to being present in several extra-
pulmonary tissues. SP-D triggers a range of anti-microbial defense 
mechanisms, including agglutination/aggregation, phagocytosis, 
and direct growth inhibition (1). SP-D is also capable of control-
ling pulmonary inflammation including allergy and asthma, and 
thus, linking innate with adaptive immunity via modulation of 
dendritic cell maturation, and polarization of helper T cells (1).
The direct nature of interaction between SP-D and Influenza 
A Virus (IAV) has been reported (3, 4), which often results in 
virus neutralization and enhanced phagocytosis (5, 6). Anti-viral 
roles of SP-D during IAV infection have been well-documented, 
principally by Hartshorn group. IAV is an enveloped RNA virus 
and a member of Orthomyxoviridae family that possesses eight 
single-stranded RNA segments with negative orientation. These 
RNA segments can encode up to 13 viral proteins, including 
two surface glycoproteins, an ion channel protein, nucleocapsid 
protein, structural scaffolding protein, a tripartite polymerase 
complex, two non-structural proteins, and three non-essential 
proteins (7). IAV is subtyped based on their surface glycoproteins, 
such as hemagglutinin (HA) and neuraminidase (NA); to date, 
there are 19 HA and 9 NA protein subtypes that have been well 
established. Both HA and NA play an important role in the host 
range, viral replication, and pathogenicity (8). Among the three 
genera of influenza viruses reported, infection by IAV is the 
most common and severe in humans, swine, and avian species. 
It is also known to cause pandemic infections, being diverse in 
host specificity. IAV is considered as a major human respiratory 
pathogen following 1918 H1N1 influenza pandemic (Spanish Flu) 
(9), which is believed to have resulted in the zoonotic transmission 
of an avian virus to a human host and has rapidly dispersed (10).
Binding of IAV to target cells is mediated via the globular head 
of HA to sialic acid (SA) receptors present on the host cell surface 
(11, 12). IAV subtypes have adapted to human preferentially via 
binding with α (2–6) linkage of SA receptors (13). Following 
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Eagle’s Medium (DMEM) (Sigma-Aldrich), supplemented with 
10% v/v fetal bovine serum (FBS), 2 mM l-glutamine, 100 U/ml 
penicillin (Sigma-Aldrich), 100  µg/ml streptomycin (Sigma-
Aldrich) and 1 mM sodium pyruvate (Sigma-Aldrich), and left 
to grow at 37°C in the presence of 5% v/v CO2 for approximately 
3  days before passaging. Since these cells were adherent, they 
were detached using 2× Trypsin-EDTA (0.5%) (Fisher Scientific) 
for 10 min at 37°C. Cells were then centrifuged at 1,200 rpm for 
5 min, followed by re-suspension in complete DMEM with FBS, 
penicillin, and streptomycin, as described above. To determine 
the cell count and viability, an equal volume of the cell suspen-
sion and Trypan Blue (0.4% w/v) (Fisher Scientific) solution were 
vortexed, followed by cell count using a hemocytometer with 
Neubauer rulings (Sigma-Aldrich). Cells were then re-suspended 
in complete DMEM for further use.
Purification of iaV subtypes
MDCK cells at 80–90% confluency were washed with sterile 
PBS twice before infection. Diluted pH1N1 (2 × 104) or H3N2 
(3.3  ×  104) (600  µl/flask) was transferred to the flask contain-
ing 20 ml of complete DMEM, and incubated at 37°C for 1 h. 
Unbound viruses were removed by washing three times with ster-
ile PBS. 25 ml of infection medium [DMEM with 1% penicillin/
streptomycin, 0.3% bovine serum albumin (BSA), and 1 µg/ml of 
l-1-Tosylamide-2-phenylethyl chloromethyl ketone (TPCK)—
Trypsin] (Sigma-Aldrich) were added to the flasks, and incubated 
at 37°C for 3 days. The virus particles were then harvested via 
centrifugation of the infection medium at 3,000 × g at 4°C for 
15 min. The supernatant obtained was centrifuged at 10,000 × g 
for 30 min at 4°C. 26 ml of supernatant was added slowly to 
new ultra-clear centrifuge tubes containing 30% w/v sucrose 
(8  ml/tube) (Sigma-Aldrich), and centrifuged at 25,000  ×  g at 
4°C for 90 min. The upper phase of the medium and the sucrose 
phase were carefully removed; IAV particles at the bottom were 
re-suspended in 100 µl of sterile PBS. Virus suspension (15 µl) 
was subsequently analyzed by SDS-PAGE and ELISA.
Tissue culture infectious Dose  
50% (TciD50) assay
Purified pH1N1 or H3N2 virus stocks were prepared with a starting 
dilution of 10−2 in DMEM and 146 µl of the diluted virus was 
added to all wells; uninfected MDCK cells were used as a control. 
46  µl of pH1N1 or H3N2 was then serially diluted (1/2log10  
up to 10−7) and incubated at 37°C for 1 h in a microtiter plate. 
1 × 105 MDCK cells, earlier trypsinised and re-suspended in 2× 
infection medium, were added to each well and incubated for 
3 days at 37°C under 5% v/v CO2 until cytopathic effect (CPE) was 
observed. After 5 days, each well was observed under microscope, 
and the number of wells that were positive and negative for CPE 
at each dilution was recorded.
expression and Purification of a 
recombinant Fragment of human sP-D 
containing neck and crD regions
A recombinant fragment of human SP-D (rfhSP-D) was 
expressed under bacteriophage T7 promoter in Escherichia coli 
BL21 (λDE3) pLysS (Invitrogen), transformed with plasmid 
pUK-D1 containing cDNA sequences for the 8 Gly-X-Y repeats, 
neck and CRD regions of human SP-D, as described previously 
(20). Briefly, a primary inoculum of 25 ml bacterial culture was 
inoculated into 500  ml of LB containing 100  µg/ml ampicillin 
and 34  µg/ml chloramphenicol (Sigma-Aldrich), grown to 
OD600 of 0.6, and then induced with 0.5  mM isopropyl β-d-1-
thiogalactopyranoside (IPTG) (Sigma-Aldrich) for 3  h. The 
bacterial cell pellet was re-suspended in lysis buffer (50  mM 
Tris–HCl pH7.5, 200  mM NaCl, 5  mM EDTA pH 8, 0.1% v/v 
Triton X-100, 0.1 mM phenyl-methyl-sulfonyl fluoride, 50 µg/ml 
lysozyme) and sonicated (five cycles, 30 s each). The sonicate was 
harvested at 12,000  ×  g for 30  min, followed by solubilization 
of inclusion bodies in refolding buffer (50  mM Tris–HCl pH 
7.5, 100 mM NaCl, 10 mM 2-Mercaptoethanol) containing 8 M 
urea. The solubilized fraction was then dialyzed stepwise against 
refolding buffer containing 4  M, 2  M, 1  M, and no urea. The 
clear dialysate was loaded onto a maltose agarose column (5 ml; 
Sigma-Aldrich) and the bound rfhSP-D was eluted using 50 mM 
Tris–HCl, pH 7.5, 100 mM NaCl, and 10 mM EDTA. The eluted 
fractions were then passed through PierceTM High Capacity 
Endotoxin Removal Resin (Qiagen) to remove endotoxin. The 
endotoxin levels were measured via QCL-1000 Limulus amebo-
cyte lysate system (Lonza), and found to be <5 pg/µg of rfhSP-D.
Direct Binding elisa
Maxisorp 96-well microtiter plates were coated with rfhSP-D 
(5, 2.5, 1.25, and 0.625 µg/well) in carbonate-bicarbonate buffer 
(CBC), pH 9.6, and incubated overnight at 4°C. After remov-
ing the CBC buffer, microtiter wells were washed with PBS 
three times, blocked with 2% w/v BSA in PBS for 2 h at 37°C, 
and then washed three times with PBST (PBS +  0.05% Tween 
20). 20 µl of concentrated pH1N1, H3N2 virus (1.36 × 106 pfu/
ml), or purified recombinant HA (2.5  µg/ml) was diluted in 
200  µl of PBS, 10  µl of diluted virus was added to each well, 
and incubated at room temperature (RT) for 2 h in buffer con-
taining 5  mM CaCl2. VSV-G pseudotyped lentivirus was used 
as a negative control. The microtiter wells were washed with 
PBST three times and the binding was probed with primary 
antibody: monoclonal anti-influenza virus H1 (BEI-Resources) 
and polyclonal anti-influenza virus H3 (BEI-Resources) antibody 
(1:5,000 dilution in PBS) for 1 h at 37°C. The wells were washed 
again with PBST and incubated with anti-mouse IgG-Horseradish 
peroxidase (HRP)-conjugate (1:5,000) (Fisher Scientific) and 
Protein A-HRP-conjugate (Fisher Scientific) in PBS (100 µl/well), 
respectively, for 1  h at 37°C. Color was developed using 3,3′, 
5,5′-Tetramethylbenzidine (TMB) substrate (Sigma-Aldrich). The 
reaction was stopped using 2 N H2SO4 and the absorbance was 
read at 450  nm using iMark™ microplate absorbance reader 
(Bio-Rad).
Far Western Blotting
rfhSP-D (5  µg) or 10  µl of concentrated pH1N1/H3N2 
(1.36  ×  106  pfu/ml) were run separately on a 12% (w/v) SDS-
PAGE, and then electrophoretically transferred onto a nitrocel-
lulose membrane (320 mA for 2 h) in 1× transfer buffer (25 mM 
Tris–HCl pH 7.5, 190 mM glycine, and 20% methanol), followed 
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by blocking overnight in 5% w/v dried milk powder in PBS 
(Sigma-Aldrich) at 4°C on a rotatory shaker. The membrane was 
then washed with PBST three times, 10 min each. For far western 
blotting, the nitrocellulose membrane was incubated with 5 µg/ml 
of rfhSP-D in PBS containing 5 mM CaCl2 for 1 h at RT and 1 h 
at 4°C. Following PBST wash, the membrane was incubated with 
primary antibodies, polyclonal rabbit anti-human SP-D, mono-
clonal anti-influenza virus H1 (BEI-Resources), or polyclonal 
anti-influenza virus H3 (BEI-Resources) in PBS (1:1,000) for 
1 h at RT. Following washing, the membrane was probed with 
secondary antibodies: protein-A-HRP-conjugate, or rabbit anti-
mouse IgG HRP conjugate (1:1,000) (Fisher Scientific) in PBS 
(100 µl/well) for 1 h at RT. After PBST wash, the blot was devel-
oped either using 3,3′-diaminobenzidine (DAB) or enhanced 
chemiluminescence substrate. For M1 detection, following 6  h 
incubation, both untreated (cells  +  virus) and treated samples 
(cells + virus + 10 µg/ml rfhSP-D) were run on the 12% (w/v) 
SDS-PAGE, and transferred onto a nitrocellulose membrane, as 
described above. The M1 expression was detected using anti-M1 
monoclonal antibody (BEI-Resources).
cell-Binding assay
A549 cells were seeded in microtiter wells using complete DMEM 
(1 ×  105 cells/well) and incubated overnight at 37°C. The wells 
were washed with PBS three times, and then rfhSP-D (10, 5, 2.5, 
and 1.25 µg/ml) was pre-incubated with pH1N1 or H3N2 virus 
(1.36 × 106 pfu/ml) diluted in 200 µl of PBS + 5 mM CaCl2; 10 µl of 
diluted virus was added to the corresponding wells, and incubated 
at RT for 2 h. Maltose-binding protein (MBP) was used as a nega-
tive control. The microtiter wells were then washed with PBS three 
times, and fixed with 4% paraformaldehyde (Fisher Scientific) for 
10 min at RT. The wells were washed again with PBS three times, 
and blocked with 2% w/v BSA in PBS for 2 h at 37°C. Monoclonal 
anti-influenza virus H1 (BEI-Resources) and polyclonal anti-
influenza virus H3 (BEI-Resources) in PBS (1:5,000) were added 
to each well and incubated for 1 h at 37°C. After washing with 
PBST three times, the corresponding wells were probed with goat 
anti-mouse IgG-HRP-conjugate (Thermo-Fisher), or Protein 
A-HRP conjugate (1:5,000) in PBS for 1 h at 37°C. The wells were 
washed again with PBST three times and the color was developed 
using TMB substrate. The reaction was stopped using 2 M H2SO4, 
followed by absorbance reading at 450 nm.
Titration assay
Maxisorp 96-well plates were coated with 0.01% collagen (Sigma-
Aldrich) and incubated at RT for 3 h. After removing the excess 
collagen, the wells were washed with PBS twice. 75,000 A549 cells 
were seeded and grown overnight at 37°C in the presence of 5% 
v/v CO2, until 75–80% confluency. Cells were washed with 1× PBS 
twice, pH1N1 or H3N2 virus (MOI of 1) diluted in pure DMEM 
with 10 µg/ml rfhSP-D was added to cells, respectively. The plates 
were incubated at 37°C for 1 h. The wells were then washed with 
PBS twice and 200 µl of infection medium was added to the cells, 
and incubated for 24 h at 37°C with 5% v/v CO2. The media of the 
infected cells in the presence or absence of rfhSP-D was collected 
and virus titer was estimated by TCID50.
infection assay Using ph1n1 and h3n2
A549 cells were cultured in complete DMEM with usual sup-
plements at 37°C in CO2 incubator until about 70–80% conflu-
ence. Cells, washed with PBS twice, trypsinised, and adjusted 
to 5 × 105 cells in 12-well plates (Fisher Scientific), were left to 
adhere overnight at 37°C in serum-free complete DMEM. Cells 
were washed in PBS before the addition of rfhSP-D (10 µg/well) 
in pure DMEM containing 5 mM CaCl2 with MOI 1 of pH1N1 
or H3N2 virus (1 h at RT and 1 h at 4°C). The pre-incubated 
virus and protein mix was then added onto the cells in a circular 
motion and incubated at 37°C for 1 h in DMEM only. Medium 
containing unabsorbed virus and rfhSP-D protein was removed, 
cells were washed with PBS twice, infection medium was added, 
and then left to incubate 2 and 6  h. The infected cells were 
detached by scrapping with a sterile cell scrapper, centrifuged at 
1,500 × g for 3 min, and frozen at −80°C until further analysis 
via qPCR.
real-Time Quantitative Pcr analysis
The infected A549 cells were lysed using a lysis solution (50 mM 
Tris–HCl pH 7.5, 200 mM NaCl, 5 mM EDTA pH 8, 0.1% v/v 
Triton X-100). Total RNA was extracted using RNase Mini Kit 
(Qiagen). Contaminating DNA was removed by DNase I treat-
ment, followed by heat-inactivation at 70°C of DNase I and 
RNase. A260 nm was used to quantify the amount of RNA using 
NanoDrop 2000/2000c (Sigma-Aldrich), and the RNA purity was 
assessed using A260/A280 ratio between 1.8 and 2.1. The isolated 
RNA was then converted into cDNA using SuperScript II Reverse 
Transcriptase (Thermo-Fisher Scientific). Oligo-dT primers were 
added to initiate cDNA synthesis and to avoid labeling of the 
rRNA and tRNA. cDNA was synthesized using high capacity 
RNA to cDNA Kit (Thermo-Fisher Scientific) using 1–2  µg of 
total RNA. Primer sequences were designed for specificity using 
the Primer-BLAST software (Basic Local Alignment Search 
Tool) (http://blast.ncbi.nlm.nih.gov/Blast.cgi) (Table  1). The 
qRT-PCR was performed using the Light Cycler system (Applied 
Biosciences). The amplification program used was at 95°C for 
5 min, followed by 45 cycles of 95°C for 10 s, 60°C for 10 s, and 
72°C for 10  s. The specificity of the assay was established by 
melting-curve analysis.
Multiplex cytokine array analysis
Supernatant from A549 cells, incubated with IAV with or without 
rfhSP-D for 24 h were collected for measuring secreted cytokines 
[TNF-α, IL-6, IL-10, IL-1α, interferon (IFN)-α, and IL-12p40], 
chemokine (eotaxin) and growth factors (GM-CSF and VEGF). 
The analytes were measured using MagPixMilliplex kit (EMD 
Millipore). 25  µl of assay buffer was added to each well of a 
96-well plate, followed by addition of 25 µl of standard, control, 
or supernatant from A549 cells infected with pH1N1 or H3N2 
(with or without rfhSP-D). 25 µl of magnetic beads, coupled to 
analytes, were added to each well, and incubated for 18 h at 4°C. 
The plate was washed with the assay buffer and 25 µl of detection 
antibodies were incubated with the beads for 1 h at RT. 25 µl of 
Streptavidin–Phycoerythrin was then added to each well and 
incubated for 30  min at RT. Following a washing step, 150  µl 
TaBle 1 | Target genes, forward primers, and reverse primers used for qPCR.

























IFN-α 5′-TTT CTC CTG CC 
T GAA GGA CAG-3′
5′-GCT CAT GAT TTC  
TGC TCT GAC A-3′
IFN-β 5′-AAA GAA GCA G 
CA ATT TTC AGC-3′
5′-CCT TGG CCT TCA 
GGT AAT GCA-3′
5
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of sheath fluid was added to each well and the plate was read 
using the Luminex Magpix instrument. Assays were conducted 
in duplicate.
Production of h1+n1 Pseudotyped 
lentiviral Particles
HEK293T  cells were co-transfected with 20  µg of pcDNA3.1-
swineH1-flag (H1 from swine H1N1 A/California/04/09) 
(Invitrogen), pcDNA3.1-swine N1-flag (N1 from swine H1N1 
A/California/04/09) (Invitrogen), pHIV-Luciferase backbone 
(Addgene), which carries a modified proviral HIV-1 genome with 
env deleted and designed to express the firefly luciferase reporter, 
and psPAX2 (Addgene). psPAX2 is a second-generation lentiviral 
packaging plasmid and can be used with second or third genera-
tion lentiviral vectors and envelope expressing plasmid. VSV-G 
lentivirus was produced in a similar way as described above, 
without H1+N1 plasmids. Supernatant containing the released 
H1+N1 pseudotyped and VSV-G lentiviral particles were har-
vested at 24 and 48 h and centrifuged at 5,000 × g for 10 min to 
remove any debris, and concentrated via ultra-centrifugation. The 
transfected HEK293T cells were lysed using lysis buffer (50 mM 
Tris–HCl pH 7.5, 200 mM NaCl, 5 mM EDTA, 0.1% v/v Triton 
X-100). The filtered supernatant and the cell lysate were analyzed 
via western blotting and luciferase reporter activity assay.
luciferase reporter activity assay
MDCK cells were cultured in supplemented DMEM as described 
earlier, until about 70–80% confluency. The harvested H1+N1 
pseudotyped particles at 24 and 48  h were used to perform 
luciferase reporter activity using luciferase one-step assay kit 
(Thermo Scientific). rfhSP-D (5 and 10  µg/ml) was used to 
determine its effect on the luciferase reporter activity; cells only, 
and cells  +  H1+N1 particles were used as controls. Readings 
were measured using a GloMax 96 Microplate Luminometer 
(Promega).
statistical analysis
Graphs were generated using GraphPad Prism 6.0 software and the 
statistical analysis was performed using a two-way ANOVA test. 
Significant values were considered based on *p < 0.1, **p < 0.05, 
***p  <  0.01, and ****p  <  0.001 between treated and untreated 
conditions. Error bars show the SD or SEM, as indicated in the 
figure legends.
resUlTs
rfhsP-D Binds Directly to iaV subtypes
Escherichia coli BL21 (λDE3) pLysS containing pUK-D1 construct 
(20) expressed a ~20  kDa protein following IPTG induction, 
compared to the un-induced bacterial cells (Figure  1A). The 
overexpressed insoluble rfhSP-D as inclusion bodies was refolded 
via denaturation and renaturation cycle. The soluble rfhSP-D frac-
tions were affinity purified using maltose–agarose column, which 
appeared as a single band on 12% SDS-PAGE (v/v) under reducing 
condition (Figure 1B). The immunoreactivity of purified rfhSP-
D was confirmed via western blotting using rabbit polyclonal 
anti-human SP-D antibody that was raised against native human 
SP-D purified from lung lavage of alveolar proteinosis patients 
(Figure 1C). The ability of pH1N1 and H3N2 subtypes to bind 
microtiter-coated rfhSP-D was examined via ELISA. As shown 
in Figure 2, rfhSP-D bound both IAV subtypes in a dose- and 
calcium-dependent manner. VSV-G pseudotyped lentivirus was 
used as a negative control RNA virus, where no significant binding 
was seen with all rfhSP-D concentrations tested. For cell-binding 
assay, A549 cells were challenged with purified pH1N1 or H3N2 
pre-incubated with a range of rfhSP-D concentrations (Figure 3). 
The maximum inhibition (50%) of cell binding was seen at 10 µg/
ml. MBP was used as a negative control protein.
rfhsP-D Binds to ha and restricts 
replication of iaV in a549 cells
Previous studies have shown that SP-D binds to the glycosylation 
site of HA1 domain on IAV (18). Far western blotting revealed 
that rfhSP-D bound to HA (70 kDa) and M1 (27 kDa) of pH1N1 
(Figure  4A) and H3N2 (Figure  4B) subtypes. As shown in 
Figure 4C, rfhSP-D was able to bind purified recombinant HA pro-
tein in a concentration-dependent manner. The binding of rfhSP-
D may inhibit cellular viral infection by restricting the interaction 
of HA with SA containing receptors, and HA-mediated fusion in 
endosomes. The interaction between rfhSP-D and HA appears to 
offer another dimension at which rfhSP-D may suppress target cell 
infection and intracellular replication. The mechanism of direct 
inhibition of IAV by rfhSP-D was thus investigated via infection 
assay. A549 cells infected with pH1N1 and H3N2 revealed an 
upregulation of M1 expression at 2 and 6 h time points (Figure 5). 
However, A549 cells, pre-treated with rfhSP-D showed down-
regulation of viral M1 expression when compared to untreated 
cells challenged with virus (Figure  5). The downregulation of 
M1 expression due to rfhSP-D pre-incubation was more effective 
in the case of pH1N1 compared to H3N2, where −8 log10 fold 
downregulation was seen at 2 h (Figure 5A). This was validated 
via western blotting, where a low M1 expression was detected 
FigUre 1 | SDS-PAGE (12% v/v) under reducing conditions showing expression and purification of a recombinant surfactant protein D (rfhSP-D). The neck  
and carbohydrate recognition domain regions were expressed in Escherichia coli BL21 (λDE3) pLysS. (a) Following induction with 0.5 mM IPTG, a ~20 kDa band 
appeared being overexpressed compared to uninduced sample. Following denaturation–renaturation cycle, the rfhSP-D was purified on an affinity column to 
homogeneity after elution with EDTA as fractions F1, F2 and F3 (B). A rabbit polyclonal antibody raised against full-length SP-D purified from human bronchoalveolar 
lavage (c) recognized the purified rfhSP-D, but not BSA that was used as a negative control protein.
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in rfhSP-D (10 µg/ml) treated sample following 6 h incubation, 
when compared to untreated samples (cells + virus) (Figure 5C). 
Furthermore, anti-IAV activity of rfhSP-D was confirmed via 
virus titration assay (Figures  5D,E). Approximately 40% titer 
reduction was seen in 10 µg rhfSP-D treated cells compared to 
untreated samples, suggesting the ability of rfhSP-D to act as an 
entry inhibitor. Differential inhibitory effects of rfhSP-D on IAV 
subtypes may reflect on the glycosylation of the HA protein of 
IAV, suggesting a correlation between HA-glycan attachment and 
susceptibility of IAV strains to inhibition by rfhSP-D that involves 
specific interaction sites on HA.
rfhsP-D Modulates Pro-inflammatory 
cytokine/chemokine immune responses 
Following Virus challenge to a549 cells
The qPCR analysis revealed that there was an upregulation of 
pro-inflammatory cytokines TNF-α and IL-6 by H3N2 strain, 
which were brought down slightly by rfhSP-D at 2 h (Figure 6A). 
However, both TNF-α and IL-6 in the case of pH1N1 were found 
to be downregulated considerably by rfhSP-D at 2  h, which 
gradually recovered by 6 h (Figure 6B). IL-6, which is crucial for the 
resolution of IAV infection, acts by inducing neutrophil medi-
ated viral clearance. An elevated level of IL-6 in lung and serum 
has been reported in patients infected with pH1N1 (21). TNF-α 
and IL-6 are the key contributors to IAV-mediated respiratory 
diseases and acute lung injury. By contrast, there was a broad 
level of downregulation of IL-12 in the case of both IAV subtypes 
incubated with rfhSP-D, suggesting a likely reduction of Th1 
response and suppression of IFN-γ production by CD4+ T cells. 
Suppressed transcript level of RANTES (1 log10 fold) by rfhSP-D 
was observed at 2 h treatment in the case of pH1N1. However, 
in the case of H3N2 strain, RANTES was downregulated by 0.5-
fold (log10) (Figure 6B) at 2 h following treatment with rfhSP-D 
compared to untreated A549 cells. Furthermore, suppression 
of IFN-α and IFN-β were also seen with rfhSP-D treatment 
at both 2 and 6 h time points (Figure 6C). Both of these type 
I IFN cytokines play a crucial anti-viral role against IAV, and 
FigUre 3 | Cell-binding assay to show binding of (a) pH1N1 and (B) H3N2 
pre-incubated with rfhSP-D to A549 cells. Microtiter wells were coated with 
A549 cells (1 × 105 cells/ml) and incubated overnight at 37°C. Varied 
concentrations of pre-incubated rfhSP-D (10, 5, 2.5, and 1.25 µg/ml) with 
pH1N1 and H3N2 virus were added to the corresponding wells, followed by 
incubation at room temperature for 1–2 h. After fixing the cells with 4% 
paraformaldehyde solution, monoclonal anti-influenza virus H1, or polyclonal 
anti-influenza virus H3 were added to corresponding well. Maltose-binding 
protein (MBP) was used as a negative control protein. The data were expressed 
as mean of three independent experiments done in triplicates ± SEM.
FigUre 2 | ELISA to show binding of rfhSP-D to (a) pH1N1 and (B) H3N2: 
microtiter wells were coated with different concentrations of rfhSP-D  
(5, 2.5, 1.25, and 0.625 µg/ml). 20 µl of concentrated pH1N1 or H3N2 virus 
(1.36 × 106 pfu/ml) was diluted in 200 µl of PBS + 5 mM CaCl2 and 10 µl of 
diluted virus was added to all the wells, and probed with either monoclonal 
anti-influenza virus H1 or polyclonal anti-influenza virus H3 antibody. VSV-G 
pseudotyped lentivirus was used as a negative RNA virus control. The data 
were expressed as mean of three independent experiments done in 
triplicates ± SEM.
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determine the rate of viral replication in the initial stages of 
infection. Suppression of type I IFN levels suggests the ability of 
rfhSP-D to reduce the rate of viral replication, thereby reducing 
the levels of INF produced by the innate immune system.
Multiplex cytokine array analysis reveals 
a Differential ability of rfhsP-D to 
Downregulate Pro-inflammatory 
cytokines and chemokines
To assess secretion of cytokines, chemokines, and growth factors 
over a period of 24 h post rfhSP-D treatment, a multiplex cytokine 
array was performed using supernatants of the IAV challenged 
and rfhSP-D treated A549 cells. rfhSP-D induced a dramatic 
suppression of some of the key pro-inflammatory cytokines 
and chemokines in the virus infected A549 cells. In the case of 
pH1N1, TNF-α, IFN-α, IL-10, IL-12 (p40), VEGF, GM-CSF, and 
eotaxin were considerably suppressed by rfhSP-D treatment at 
24 h (Figure 7A). However, these suppressive effects on IL-10, 
VEGF, eotaxin, and IL-12 (p40) were not so evident in the case 
of H3N2 subtype, with the exception of TNF-α, IFN-α, and 
GM-CSF (Figure 7). These data seem to suggest that the extent 
of immunomodulatory effect of rfhSP-D on host cells can vary 
considerably in a IAV subtype-specific manner.
rfhsP-D Binds to h1+n1 Pseudotyped 
lentivirus and reduces luciferase 
reporter activity
H1+N1 pseudotyped lentiviral particles were produced as a safe 
strategy to study the differential or combinatorial involvement of 
HA or NA viral glycoproteins in the recognition and neutraliza-
tion of IAV by rfhSP-D. The production of lentiviral particles 
pseudotyped with envelope proteins H1+N1 was carried out 
by co-transfecting HEK293T cells with plasmid containing the 
coding sequence of the indicated H1+N1, pHIV-Luciferase 
backbone, and psPAX2. Purified H1+N1 pseudotyped particles 
FigUre 4 | Far western blot analysis to show rfhSP-D binding to purified (a) pH1N1 and (B) H3N2: 10 μl of concentrated virus (1.36 × 106 pfu/ml) was first run on 
the SDS-PAGE under reducing conditions, and then transferred onto a nitrocellulose membrane and incubated with 5 µg of rfhSP-D. The membrane was probed 
with anti-rabbit SP-D polyclonal antibodies. rfhSP-D bound to HA (70 kDa) and M1 (27 kDa) in the case of both pH1N1 and H3N2 subtypes. (c) ELISA to show  
the binding of rfhSP-D to purified recombinant hemagglutinin (HA) (μg/ml). VSV-G was used as a negative control. The data were expressed as mean of three 
independent experiments carried out in triplicates ± SEM. Significance was determined using the unpaired one-way ANOVA test (***p < 0.0001) (n = 3).
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and cell lysate harvested at 24 and 48 h were analyzed via western 
blotting, and the expression level of HA was determined using 
anti-H1 monoclonal antibody (Figure  8A); HA was evident at 
70 kDa. Far western blotting revealed binding of rfhSP-D to HA at 
70 kDa (Figure 8B), suggesting that the binding of rfhSP-D to HA 
is crucial for the inhibition of viral infectivity. Purified H1+N1 
pseudotyped particles harvested at 24 and 48  h were used to 
transduce MDCK cells to measure the luciferase reporter activity 
assay. Higher levels of luciferase reporter activity were observed 
at 24 h when compared to 48 h post-transfection (Figure 8C). 
Thus, pseudotyped particles harvested at 24  h were used to 
transduce MDCK cells with or without rfhSP-D (5 and 10 µg/ml) 
(Figure  8D). Nearly 50% reduction in the luciferase reporter 
activity was observed with 10 µg/ml of rfhSP-D compared to cells 
challenged with H1+N1 pseudotyped particles. This suggested an 
entry inhibitory role of rfhSP-D against IAV.
DiscUssiOn
Respiratory tract infection caused by IAV is associated with up 
to half a million mortality rates worldwide and five million cases 
of morbidity per year. A new swine-origin H1N1 IAV, identified 
in April 2009, spread worldwide, and was officially declared 
pandemic in June 2009. There are concerns that H1N1 or H3N2 
viruses reassort with existing H5N1 virus using bird or pig as 
intermediate hosts, giving rise to more pathogenic IAV. Thus, it 
is important to understand molecular mechanisms of host’s first 
line of defense against IAV in order to design and develop novel 
and effective anti-IAV strategies. SP-D expressed at the mucosal 
sites including lungs plays an important role during IAV infec-
tion (22). SP-D has been shown to have a wide range of innate 
immune roles including neutralization, agglutination, opsoni-
zation and clearance of viruses including IAV. The binding ability 
of rfhSP-D to HIV-1 gp120 was reported, primarily in a dose- and 
calcium-dependent manner (23). Human SP-D has also been 
shown to bind IAV-HA and NA, resulting in the inhibition of 
viral attachment and entry into the host cells (24). However, the 
mechanism of direct inhibition of IAV and pseudotyped viral 
particles by SP-D and subsequent immune response is not fully 
explored.
Using two different IAV subtypes (pH1N1 and H3N2), we have 
shown that the entry inhibitory capability of rfhSP-D is not limited 
FigUre 5 | rfhSP-D restricts replication of (a) pH1N1 and (B) H3N2 in target human A549 cells. M1 expression of both pH1N1 and H3N2 influenza A virus (IAV) 
(MOI 1) after infection of A549 cells at differential time points at 2 and 6 h. A549 cells were incubated either with pre-incubated pH1N1 and H3N2 with (10 µg) or 
without purified rfhSP-D. Cell pellets were harvested at 2 and 6 h to analyze the M1 expression of IAV. Cells were lysed, and purified RNA extracted was converted 
into cDNA. Infection was measured via qRT-PCR using M1 primers and 18S was used as an endogenous control. Results shown are normalized to M1 levels at 2 h 
untreated. Significance was determined using the unpaired one-way ANOVA test (**p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3). (c) Western blotting to 
shown M1 expression in both untreated (cells + virus) and treated (cells + virus + 10 µg/ml rfhSP-D) following 6 h incubation. Titration assay to show the anti-IAV 
activity of rfhSP-D (10 µg/ml), using both pH1N1 (D) and H3N2 (e) subtypes. A549 cells were infected with pH1N1/H3N2 (MOI 1) for 24 h. Then, the supernatants 
were collected and virus titers measured using a TCID50 assay. Treatment with rfhSP-D reduced viral titers by approximately 40%, suggesting that rfhSP-D acts as 
an entry inhibitor.
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to a particular IAV subtype. To identify the interaction of rfhSP-D 
with IAV viral proteins, protein–protein interaction studies were 
carried out via ELISA, cell-binding assay, and far western blot. 
The ELISA (Figure 2) and cell-binding assay (Figure 3) revealed 
the maximal binding of rfhSP-D to both pH1N1 and H3N2 
IAV subtypes at 5  µg/ml, and the maximum inhibition of cell 
binding was seen at 10 µg/ml of rfhSP-D. Furthermore, rfhSP-D 
bound purified recombinant HA protein in a concentration- and 
calcium-dependent manner (Figure  4C). rfhSP-D bound HA 
(70 kDa) and M1 (25 kDa) (Figure 4). N-linked oligosaccharides 
FigUre 6 | Continued
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FigUre 6 | Differential mRNA expression profile of A549 cells challenged with pre-incubated (a) pH1N1, (B) H3N2 with rfhSP-D, and (c) expression levels of type I 
interferon (IFN) subtypes in both untreated and treated samples. The expression levels of cytokines and chemokine were measured using qRT-PCR and the data 
were normalized via 18S rRNA expression as a control. The relative expression (RQ) was calculated by using cells only time point as the calibrator. The RQ value 
was calculated using the formula: RQ = 2−ΔΔCt. Assays were conducted in triplicates and error bars represents ± SEM. Significance was determined using the 
unpaired one-way ANOVA test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001) (n = 3).
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found on the IAV envelope glycoproteins (HA and NA) are known 
to be recognized by the CRD region of SP-D. Thus, HA-exposed 
glycans differing in location and numbers between IAV subtypes 
may be responsible for this interaction. rfhSP-D is likely to inhibit 
IAV infection by preventing the HA interaction with SA contain-
ing receptors. A reverse genetic approach has been used to analyze 
the role of N-glycosylation sites on the head of H1 in modulating 
sensitivity to SP-D in vitro and in vivo (25). It was found that HA 
Asn-144 was a critical factor in sensitivity to SP-D (25).
We also examined the immune response of A549 lung epi-
thelial cells following IAV challenge in the presence or absence 
of rfhSP-D, which can impact upon cellular infection and viral 
replication. Therefore, the ability of rfhSP-D to modulate viral 
replication as well as inflammatory immune response following 
IAV challenge was examined via infection assay, qPCR, and mul-
tiplex cytokine array. The key aspect of host–pathogen interaction 
arising out of this study is the ability of rfhSP-D-bound pH1N1 
and H3N2 to undergo suppressed replication, as evident by the 
expression of M1 gene. M1 is a matrix protein of IAV that lies 
beneath the lipid layer and is the most abundant protein, which 
is essential for viral stability and integrity. Thus, it plays a critical 
role in the recruitment and assembly of viral sites, nuclear export 
of viral RNPs, and thus, establishing the host components for 
viral budding (26). rfhSP-D suppressed the expression of M1 in 
pH1N1 (Figure 5A) at 2 h, while downregulating at 6 h in the case 
of H3N2 (Figure 5B). In addition, a lowered M1 expression was 
detected via western blot in the rfhSP-D treated sample compared 
to untreated sample following 6 h incubation (Figure 5C). Viral 
replication was also reduced in the presence of rfhSP-D as evident 
in Figures 5D,E. This suggests that rfhSP-D could act as an entry 
inhibitor against the subtypes tested (pH1N1 and H3N2). It is 
known that HA undergoes N-linked glycosylation, leading to 
modulation of antigenicity, fusion activity, receptor-binding 
specificity, and immune evasion of IAV. Therefore, SP-D can play 
an important role in innate defense against IAV as entry inhibi-
tor by interfering with glycosylation sites and binding to glycans 
on the viral HA. It has been reported that the combinatorial 
substitutions of D325A/S+R343V in a trimeric neck and CRD 
fragment of human SP-D markedly increased anti-viral activity 
against pandemic IAV. This is because of the increased ability of 
the mutant to block the SA binding sites, aggregate the virus and 
reduce viral uptake (27).
Our qPCR data demonstrated an increased expression level 
of TNF-α and IL-6 in the case of H3N2 subtype (Figure  6B) 
FigUre 7 | Multiplex cytokine array analysis of supernatants that were collected at 24 h time point. A549 cells were infected with pH1N1 (a) and H3N2 (B), treated 
with 10 µg/ml of rfhSP-D. Cytokines (TNF-α, IL-6, IL-10, IL-1α, IFN-α, and IL-12p40), chemokine (eotaxin), and growth factors (GM-CSF and VEGF) were measured 
using a commercially available MagPix Milliplex kit (EMD Millipore). Assays were conducted in triplicates and error bars represent ± SEM (n = 3); significance was 
determined using unpaired one-way ANOVA test (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001).
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compared to pH1N1. However, when pH1N1 was treated with 
rfhSP-D, TNF-α and IL-6 were suppressed at 2 h (Figure 6A), 
which recovered later (6 h). Elevated TNF-α and IL-6 levels can 
contribute to virus-mediated respiratory diseases or acute lung 
injury. IL-12 was considerably downregulated by rfhSP-D in 
the case of both IAV subtypes, suggesting the likely suppression 
of Th1 immune response. mRNA expression of RANTES was 
10-fold (log101 fold) downregulated in the presence of rfhSP-D 
at 2 h time point in pH1N1 compared to A549 cells challenged 
with IAV. However, cells, challenged with H3N2 and treated 
with rfhSP-D, were seen to have log10 one-fold downregulation 
of RANTES expression. In this study, we also report the ability 
of rfhSP-D (10 µg/ml) to downregulate both IFN-α and IFN-β 
expression (Figure 6C) at 2 and 6 h. Higher expression levels of 
IFN-α and IFN-β were detected in the untreated (cells + virus) 
sample, which was threefold (log10 fold) downregulated in the 
presence of rfhSP-D at 6 h. This suggests that when cells were incu-
bated with pH1N1/H3N3 (MOI 1), higher levels of both IFN-α 
and IFN-β were produced by A549 cells to clear the virions. Since 
addition of rfhSP-D caused inhibition of viral replication, lower 
levels of INF were detected. Recently, the E3 ubiquitin ligase, 
TRIM29, has been shown to be a negative regulator of type I IFN 
responses in the lungs post-IAV challenge in vivo. TRIM29 acts 
by inhibiting IFN-regulatory factors and signaling via NF-κB, 
leading to degradation of NF-κB essential modulator (28). 
Whether rfhSP-D works via similar mechanisms is worth further 
investigation using SP-D gene-deficient mice (29). In addition, 
cytokine array analysis using supernatants that were collected at 
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FigUre 8 | Continued
FigUre 8 | (a) Western blotting to show the expression of influenza A virus-hemagglutinin (HA) protein in purified H1+N1 pseudotyped lentiviral particles and  
cell lysate at 24 and 48 h. The presence of HA was identified at 70 kDa. (B) Far western blotting to show rfhSP-D binding in both purified H1+N1 pseudotyped 
lentiviral particles and cell lysate at 24 and 48 h. HA was evident at 70 kDa when probed with rfhSP-D. (c) Luciferase reporter activity of purified H1+N1 
pseudotyped lentiviral particles at 24 and 48 h, and (D) Luciferase reporter activity of rfhSP-D treated MDCK cells transduced with these lentiviral particles. 
Significance was determined using the unpaired one-way ANOVA test (*p < 0.05 and ****p < 0.0001) (n = 3).
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24 h showed considerable downregulation of some of the key pro-
inflammatory cytokines, chemokines, and other soluble factors in 
the presence of rfhSP-D. The downregulation of various humoral 
factors by rfhSP-D treatment could also facilitate the prevention 
of life-threatening secondary bacterial infections that may be 
caused by aberrant virus-mediated immune modulation.
In this study, we have produced the second-generation 
lentiviral vectors pseudotyped for H1+N1 of IAV. This system 
contains a single packaging plasmid (psPAX2) encoding genes 
including Gag, Pol, and Tat. pHIV-Luciferase was used as a lenti-
viral transfer plasmid, which is flanked with long terminal repeat 
(LTR) sequences, and designed to express the firefly luciferase 
reporter. Thus, pHIV-Luciferase is “replication incompetent” 
which contains an additional sequence deletion in the 3′ LTR 
leading to viral “self-inactivation” post-integration. This was 
selected as a safe alternative method to mimic the structure 
and surfaces of IAV, and to prove rfhSP-D as an entry inhibi-
tor in cells transduced with pseudotyped IAV particles that are 
restricted to only one replicative cycle. The lentiviral particles 
pseudotyped with H1+N1 were analyzed via SDS-PAGE and 
western blotting. Expression of HA in purified H1+N1 pseudo-
typed lentiviral particles from transfected HEK293T  cells was 
assessed by western blotting using anti-H1 monoclonal antibody 
(Figure 8A). H1+N1 pseudotyped lentiviral particles, purified 
via ultra-centrifugation,  were used to investigate the combinato-
rial or differential involvement of viral envelope glycoproteins in 
the recognition and neutralization of HA by rfhSP-D. Incubation 
of rfhSP-D with these H1+N1 pseudotyped lentiviral particles 
was found to facilitate its binding to HA that appeared at 70 kDA 
in the far western blot (Figure 8B). To validate the effectiveness 
of rfhSP-D as an entry inhibitor of IAV, luciferase reporter activ-
ity assay was performed. Nearly 50% luminescent signal was 
seen with 10 µg/ml of rfhSP-D when compared to MDCK cells 
challenged with H1+N1 pseudotyped lentiviral particles alone. 
This, therefore, suggested the ability of rfhSP-D to inhibit viral 
infectivity through binding to cell surface bound HA found on 
the infected MDCK cells.
In summary, suppression of M1 expression, pro-inflammatory 
cytokine response, as well as luciferase reporter activity in target 
A549 cells by rfhSP-D highlight its potential as a therapeutic 
molecule in an entry inhibitory role against IAV.
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